Vertex Pharmaceuticals (VRTX)
Health Care · Specialty Biopharmaceuticals / Gene Therapy
Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
What Vertex Pharmaceuticals does
Vertex Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes medicines for serious diseases. The company's primary revenue driver is its portfolio of cystic fibrosis (CF) medicines, including KALYDECO, ORKAMBI, SYMDEKO, SYMKEVI, TRIKAFTA, and KAFTRIO. Vertex also commercializes CASGEVY, a gene-editing therapy for sickle cell disease and beta thalassemia, and JOURNAVX for acute pain, alongside ongoing development programs in neuropathic pain and other serious conditions.
Themes: ["Cystic fibrosis treatment","Gene editing / CRISPR","Sickle cell disease / beta thalassemia","Specialty pain management","Cell and gene therapy","Precision medicine"]
Fundamentals
- Price$498.43 as of 2026-07-08 close
- Market cap$130.3B as of 2026-07-09
- 1-year return+6.9% as of 2026-07-08 close
- P/E30.05 as of 2026-07-09
- Net margin+35.5% as of 2026-07-09
- Gross margin+86.2% as of 2026-07-09
- ROE+23.9% as of 2026-07-09
- Debt / equity0.01 as of 2026-07-09
- Revenue growth (YoY)+10.1% as of 2026-07-09
- Revenue CAGR (3y)+10.4% SEC XBRL
- Beta0.29 as of 2026-07-09
Key risks (from latest filing)
["Heavy concentration of net product revenues in CF medicines; potential manufacturing/supply disruptions, competitive threats, or loss of market acceptance could materially harm revenues and operations","Commercial success of CASGEVY and JOURNAVX is uncertain; CASGEVY faces complex manufacturing, high cost-of-goods, and reimbursement challenges; JOURNAVX faces competition from lower-cost alternatives in a competitive pain market","Significant exposure to pricing and reimbursement pressures from government health programs and third-party payors; increasing focus on cost containment, price controls, and value-based pricing globally could constrain revenues"]
Fundamentals: Finnhub, as of 2026-07-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.